{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-03-18",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Dublin",
      "state": "OH",
      "country": "United States",
      "classification": "Class II",
      "openfda": {
        "application_number": [
          "NDA213051"
        ],
        "brand_name": [
          "OZEMPIC"
        ],
        "generic_name": [
          "ORAL SEMAGLUTIDE"
        ],
        "manufacturer_name": [
          "Novo Nordisk"
        ],
        "product_ndc": [
          "0169-1704",
          "0169-1715",
          "0169-1709",
          "0169-4303",
          "0169-4307",
          "0169-4314",
          "0169-4815",
          "0169-4804",
          "0169-4809"
        ],
        "product_type": [
          "HUMAN PRESCRIPTION DRUG"
        ],
        "route": [
          "ORAL"
        ],
        "substance_name": [
          "SEMAGLUTIDE"
        ],
        "rxcui": [
          "2200644",
          "2200650",
          "2200652",
          "2200654",
          "2200656",
          "2200658",
          "2707547",
          "2707549",
          "2707551",
          "2707553",
          "2707555",
          "2707557",
          "2736944",
          "2736946",
          "2736948"
        ],
        "spl_id": [
          "dfe441cd-c20f-452b-a8a5-3a6017b6b006"
        ],
        "spl_set_id": [
          "27f15fac-7d98-4114-a2ec-92494a91da98"
        ],
        "package_ndc": [
          "0169-1715-30",
          "0169-1715-90",
          "0169-1704-30",
          "0169-1709-30",
          "0169-4303-01",
          "0169-4303-13",
          "0169-4303-90",
          "0169-4303-93",
          "0169-4303-30",
          "0169-4303-99",
          "0169-4307-01",
          "0169-4307-13",
          "0169-4307-30",
          "0169-4314-01",
          "0169-4314-13",
          "0169-4314-30",
          "0169-4815-30",
          "0169-4815-90",
          "0169-4804-30",
          "0169-4809-30"
        ],
        "is_original_packager": [
          true
        ],
        "nui": [
          "N0000178480",
          "M0160181",
          "N0000020058"
        ],
        "pharm_class_epc": [
          "GLP-1 Receptor Agonist [EPC]"
        ],
        "pharm_class_cs": [
          "Glucagon-Like Peptide 1 [CS]"
        ],
        "pharm_class_moa": [
          "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"
        ],
        "unii": [
          "53AXN4NNHX"
        ]
      },
      "product_type": "Drugs",
      "event_id": "87512",
      "recalling_firm": "Cardinal Health Inc.",
      "address_1": "7000 Cardinal Pl",
      "address_2": "N/A",
      "postal_code": "43017-1091",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "FL, GA, SC",
      "recall_number": "D-0536-2021",
      "product_description": "Rybelsus (semaglutide) Tablets 7 mg Once daily Each tablet contains 7 mg semaglutide 30 tablets 3 blister packs. Each pack contains 10 tablets. Rx only NDC 0169-4307-13 Manufactured by: Novo Nordisk A/S DK-2880 Bagsvaerd, Denmark",
      "product_quantity": "1189 cartons",
      "reason_for_recall": "CGMP Deviations: Intermittent exposure to temperature excursion during storage.",
      "recall_initiation_date": "20210315",
      "center_classification_date": "20210524",
      "termination_date": "20240617",
      "report_date": "20210602",
      "code_info": "K082347"
    }
  ]
}